NCT Number: NCT01869855
A Prospective Randomized Study Evaluating the Recurrence Rate of Chronic Subdural Hematoma After Placing a Subperiosteal Drainage Compared to a Subdural Drainage
The aim of our study is to investigate in randomized controlled fashion whether the recurrence and complication rate, after insertion of subperiosteal drainage in the treatment of chronic subdural haematoma, is higher compared to insertion of subdural drainage.
We hypothesize that patients treated with a subperiosteal drainage do not show higher recurrence rates than those treated with a subdural drainage, and suffer less complications.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Neurosurgery Kantonsspital Aarau, Aarau, Canton of Aargau, Switzerland
About this study
Chronic subdural haematoma (cSDH) is one of the most frequent neurosurgical entities, affecting elderly people and associated with substantial morbidity and mortality. Its incidence is reported to be 1.7-13.1 per 100000 inhabitants per year, yet there has been a steady increasing incidence as the result of prolonged life expectancy in recent years. Surgical treatment is recommended in case of neurological symptoms. In the only evidence based review of the different surgical treatment modalities of cSDH, Weigels study group concluded that bure-hole craniostomy with irrigation and drainage has the best cure to complication ratio. A randomized controlled study of Santarius and his colleagues showed a reduced recurrence and mortality while placing a subdural drainage compared to no drainage after burr hole evacuation of cSDH. Gazzeri et al. and Zumofen et al. used closed subperiosteal drainage instead of the commonly used subdural drainage. They showed equal or superior results in outcome, complications and postoperative symptoms compared to previous studies. Since the subperiosteal drainage is not positioned in direct contact to cortical structures, bridging veins or haematoma membranes it is considered safer and should be favored over a subdural drainage. Bellut et al. compared in their institute retrospectively 48 patients treated with subperiosteal drainage to 65 patients with subdural drainage and found no difference in recurrence rate of cSDH, yet less mortality and fewer serious complications in the group treated with subperiosteal drainage. However in their study none of the results showed a significant difference, and they concluded that further randomized studies with larger patient number are needed. In a recently published prospective randomized study Kaliaperumal et al. concluded that the recurrence rate in subperiosteal drainage is equal to subdural drainage, yet the modified ranking scale(mRS) of the patients with subperiosteal drainage after 6 months was significantly better. However, the mRS score preoperative were better in the subperiosteal drain group causing a statistical bias. In addition the amount patients studied was small (25 per group) and the recurrence rate was overall at 0%, with a very low morbidity and mortality compared to the literature. Due to these bias the authors recommend further prospective and randomized studies with larger group of patients.
To date in neurosurgery practice evidence based guidelines on which drainage should be used in cSDH do not exist and both methods, subdural drainage and subperiosteal drainage, are being practiced, depending on the institute and/or the practicing neurosurgeon.
The aim of our study is to investigate in randomized controlled fashion whether the recurrence and complication rate, after insertion of subperiosteal drainage in the treatment of chronic subdural haematoma, is higher compared to insertion of subdural drainage.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patient at least 18 years of age presenting with a symptomatic chronic subdural hematoma
- Chronic subdural hematoma verified on cranial CT or MRI
Exclusion criteria
- The surgeon decides based on intraoperative conditions to perform a craniotomy (e.g. acute hematoma indicating a craniotomy)
- Chronic subdural hematoma caused by another underlying illness (e.g. caused by over-drainage of a vp-shunt)
- no informed consent
Treatment and study plan
Subperiosteal Drainage
ProcedurePrimary outcomes
-
Recurrence Rate
Time frame: within the first 12 months postoiperatively
Secondary outcomes
-
Complication rate (Morbidity)
Time frame: within the first 12 months postoperatively
-
Mortality
Time frame: within the first 12 months postoperatively
-
Outcome: Markwalder Score
Time frame: within the first 12 months postoperatively
-
Outcome: modified Ranking Score
Time frame: within the first 12 months postoperatively
-
Outcome: Glasgow Outcome Score
Time frame: within the first 12 months postoperatively
Sponsors and collaborators
Lead sponsor
Kantonsspital Aarau
Other
Registry information
Official study title
Use of Subperiosteal Drainage Versus Subdural Drainage in Chronic Subdural Hematomas Treated With Burr-Hole Trepanation: a Randomized Controlled Trial
Important dates
- Study start
- 2013
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Jun 5, 2013
- Registry last updated
- Jun 27, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Chronic Subdural Hematoma and Aspirin
NCT03120182
Brain Diseases, Cardiovascular Diseases
Basel, Switzerland
View Trial DetailsDartmouth Middle Meningeal Embolization Trial (DaMMET)
NCT04270955
Brain Diseases, Cardiovascular Diseases
Lebanon, New Hampshire, United States
View Trial DetailsMicrofabricated Microcatheter Advantages in Middle Meningeal Artery Embolization: an Early Experience at a Single Center
NCT07324551
Brain Diseases, Cardiovascular Diseases
Columbus, Ohio, United States
View Trial DetailsPuerto Rico Embolization of the Middle Meningeal Artery for the Treatment of Chronic Subdural Hematoma Trial (PREMMA)
NCT06466733
Brain Diseases, Cardiovascular Diseases
View Trial Details